Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies
- 1 January 2004
- journal article
- clinical trial
- Published by Taylor & Francis in Cancer Investigation
- Vol. 22 (5) , 663-669
- https://doi.org/10.1081/cnv-200032899
Abstract
Although conventional doxorubicin demonstrates broad activity, its clinical use is limited by cardiotoxicity. A more recent analysis suggests conventional doxorubicin-related cardiotoxicity occurs ...Keywords
This publication has 11 references indexed in Scilit:
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Anthracyclines in the Treatment of Gynecologic MalignanciesGynecologic Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of ChemotherapyCancer Investigation, 2001
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- Anthrazykline in der KrebstherapieDrugs, 1997
- Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac CatheterizationAnnals of Internal Medicine, 1978